International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/

Vol. 51 No. 1 June 2025, pp. 56-88

Future Perspectives On The Diagnosis And Management Of Neonatal Bacterial Sepsis: Overcoming Current Challenges In Clinical Practice: Review

Maged Naser [1], Mohamed M. Nasr [2], Lamia H. Shehata [3]

[1] Mazahmiya Hospital, Ministry of Health, Kingdom of Saudi Arabia, Department of ob/gyn,
[2] Consultant of General and Endoscopic Surgery (MD, FRCS)
[3] Care National Hospital, Department of Radiology
Corresponding Author: Maged Naser

Abstract: Sepsis remains the2ndcause of death amongst neonates after the pathological consequences of extreme prematurity. On this assessment we summarized knowledge approximately pathogens causing early onset sepsis (EOS) and Late-onset sepsis(LOS),the role of perinatal risk factors in determining the EOS danger, and the tools used to reduce unnecessary antibiotics. New molecular assays should enhance the accuracy of standards blood cultures, providing the opportunity fora quick and sensitive method. Exceptional sepsis standards and biomarkers are available to date, but further research is needed to guide use of antibiotics in line with these tools. beyond the historic antibiotic regimens in EOS and LOS episodes, antibiotics should be based totally at the local flora and promptly modulated if precise pathogens are recognized. The possibility of an antibiotic lock therapy for central venous catheters has to be simlly investigated. Artificial intelligence could help us to personalize remedies and reduce the increasing trend of multidrug-resistant bacteria.

keywords: early-onset sepsis, late-onset sepsis, sepsis calculator, blood culture, PCR assays, biomarkers, c-reactive protein, procalcitonin, presepsin, antibiotic lock remedy

I. Introduction

Bacterial sepsis nonetheless represents one of the essential causes of death, disability, and intake of health-care resources for millions of people every year in every age class [1].Within the pediatric and neonatal age, notwithstanding a worldwide reduction in average mortality in the final 20years, the largest reports suggest a growing prevalence of severe sepsis[2],which additionally displays an increase within the population of individuals with persistent comorbidities , and consequently extra vulnerabilities, and there's a growing trend of bacterial' resistance to antibiotics and an increase in opportunistic infections. For biological reasons related to the functional maturity of the immune system, the most premature newborn, together with newborns, are the most affected by sepsis, even in high-income countries. The chance of acquiring sepsis is inversely proportional to gestational age (GA), with the most premature newborns being at the best threat of it [3]. The alternative important threat element of sepsis is the pre-term period newborns' want for invasive ways to survive for the duration of hospitalization in Neonatal intensive Care units (NICUs). within the context of intensive care, it's miles often necessary to interrupt natural limitations towards infection: the skin is tormented by

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 51 No. 1 June 2025, pp. 56-88

plasters, catheters, surgery, and so forth., and the mucosa via ventilation, nutrition, and drugs. This obviously compromises the child's already susceptible possibilities of defence towards bacterial invasion. In the neonatal population, very premature babies, with a gestational age of 23–27 weeks, survive longer now than within the past [4].Nevertheless,sepsis stays the2nd cause of death among those babies afterthepathological outcomes of extreme prematurity. its miles envisioned that 12–13% of deaths amongst neonates of 22–40 weeks are as a consequence of this devastating pathology, and about 40% of all deaths involve neonates born earlier than 25 weeks [5].

1. Current Classification of Neonatal Sepsis

Neonatal sepsis is described in a spread of approaches, consisting of microbiological culture, laboratory testing out, and clinical symptoms, in place of adults and pediatric sepsis, that is defined based on organ failure [6]. Neonatologists divide neonatal sepsis via a temporal criterion of the onset of symptoms. Neonatal sepsis is described as early (Early Onset Sepsis—EOS) if the clinical symptoms appear within the first 72 h of life, and late onset (late Onset Sepsis—LOS) in the event that they arise after the first 72 h of life, or anyhow after 48 h from admission to the ward. This subdivision is beneficial to crudely however fast apprehend the beginning ofthe infection (maternalorenvironmental),the category of responsible germs, and to begin an empirical however more or less oriented antibiotic therapy. In reality, the bacteria responsible for EOS sepsis are in the main unique from those for LOS sepsis[7,8].

The well timed start of antibiotics, in terms of hours, is one of the ways to reduce mortality from sepsis in the newborn, as well as in the older baby, and it's far essential to the early reduction of infection, as is the choice of antibiotics with a targeted antibacterial spectrum to the bacteria, once the consequences of the microbiological tests are to be available [9].

1.1. Early-Onset Sepsis

EOS is generally caused by maternal–fetal transmission of the bacteria, a mechanism of infection additionally known as vertical transmission. The onset of symptoms is generally within 72 h from beginning, however of the 7 randomized controlled trials (RCTs) that defined EOS, one has a look at stated early onset as bobbing up < 48 h of life, 5 research as < 72 h, and one observe as < 5 days of life. Conversely, of the 8 available RCTs that mentioned LOS, all recognized late-onset sepsis episodes as arising ≥72 h of existence [6].Group B Streptococcus (GBS) and Escherichia coli represent the maximum common causing agents of EOS, accounting for 38% and 23% of episodes, respectively [10]. Those statistics are reversed in the preterm period populace, as E. coli debts for 50% of cases, while GBS is answerable for most effective 20–25% of instances [11]. Even though GBS is greater common place overall, E. coli continues to be the number one reason of EOS-related morbidity and death amongst premature infants [12,13].Considering the fact that 1990, the 12 months wherein screening of pregnant women colonized through the bacterium commenced, and the usage of intrapartum antibiotic prophylaxis changed into introduced, there has been an amazing reduction in infections due to GBS. GBS remains, in any case, a primary cause of EOS and neonatal and adult meningitis . Few of the 10 recognised GBS serotypes (Ia, Ib, and II-IX), serotypes Ia, III, and V are the most extensive in newborns and babies as much as 90 days of life. as much as 50% of newborns who contract GBS meningitis and survive it have outcomes of variable severity. Thus far, numerous preventive strategies had been followed to lessen early-onset GBS disease (EOD, with the onset at 0–6 days of life), and between 1990 and 2015 inside America, the prevalence of GBS sepsis reduced from 1.8 to 0.23 in keeping with one 1000 live births [14]. Inside the United States, pre-natal vaginal–rectal screening at 35 and 37 weeks of gestation, and the management of intrapartum antibiotic prophylaxis (IAP), were very powerful at reducing the incidence of EOD. This drastic reduction is also located in different high-income countries that undertake pre-natal screening, including Italy, for which we've got statistics from the nearby surveillance of Emilia Romagna. In Italy, the envisioned occurrence of streptococcal EOS is 0.20/1000 live births [15]. But, the reduction turned into done via the large use of intrapartum antibiotics (about 35% of pregnant women in Emilia-Romagna receive an IAP). Other Northern European countries (including England and Holland), or African nations (South Africa), do now not display women before delivery, and administer intrapartum antibiotic prophylaxis handiest to those with risk factors [16].

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 51 No. 1 June 2025, pp. 56-88

With this second approach, the EOD did no longer reduce, and in a few instances it even extended. finally, no strategy had any effect on late-onset GBS contamination (LOD, onset at 7–90 days of life), the occurrence of which remains unchanged throughout the sector. Late-onset infection with meningitis (with frequent lengthy term results) in nearly half of of instances. Itis, consequently, clear that techniques aimed toward lowering the usage of intrapartum antibiotics and preventing both varieties of GBS infection (EOD and LOD) are important. Currently, studies are centred on the preparation of vaccines, but up to now, no kind of vaccine has but been marketed [17]. Its miles anticipated that to locate a 75% reduction in EOD and LOD in countries with an ailment incidence of over 1/1000 births, it would be important to enrol about 60,000 pregnant women to take a look at the effectiveness of the vaccine if this saves in opposition to 90% of circulating serotypes. This degree considers the difficulty of reading the effectiveness of vaccines towards GBS, which despite the fact that reached section II [17].

1.2. Late-Onset Sepsis

LOS happens after 72 h of life, throughout hospitalization, and specifically affects newborns at unique risk, along with premature newborns hospitalized in the NICU. LOS prevalence varies from 15% to 36% of hospitalized newborns, relying on the care context. In the genesis of those infections, biological elements such as prematurity and all invasive processes play the primary position, and the mortality rate in infected patients is approximately four times that of non-inflamed patients. The accountable bacteria of LOS are specific from the ones of EOS. commonly, sanatorium-obtained LOS are generally resulting from pathogens from extensive care vegetation or saprophytic of the pores and skin, along with Gram-positive bacteria (69%), Coagulase negative Staphylococci (CoNS) (40%), Gram-negative-organism (29%), or fungi (3%). Conversely, in a recent population-primarily based observe by way of Giannoni et al., E. coli and GBS accounted for 41% and 41% of community-obtained LOS episodes, described as LOS with the onset ≤48 h after admission to the ward. [10].

Fundamental pathogens involved in early-onset and late-onset sepsis.

however, the paradigm EOS/LOS is based totally on discovered epidemiological data from high-income countries (HIC), while this concept can be less useful for predicting the pathogen spectrum of neonatal sepsis in low-income and middle-income countries (LIC and MIC, respectively) [18]. Despite the fact that global occurrence statistics are lacking, the overall incidence of new child sepsis is decrease in HIC than in LIC [18]. Pathogens including Klebsiella spp. may account for an extensive ‘extra’ burden of new child sepsis in LIC settings, outweighing organisms extra regularly seen in HIC settings.

presently, the irrational use of antibiotics, frequently used for “preventive purposes”, is leading to the emergence of antibiotic-resistant bacterial strains, which themselves purpose intractable sepsis. Intrapartum antibiotic prophylaxis for GBS reputation may exchange the etiology of EOS, with some studies displaying E. coli surpassing GBS as a number one cause of EOS [19]. Administered antibiotics impact the newborn’s microbiome, tipping the balance toward horizontally in place of vertically received microbes [20]. For these motives, there's a notable deal of studies at the reduction of the use of prophylactic antibiotics, the dissemination of the principles of antibiotic stewardship, and the identity of the standards for starting antibiotic therapy and the newborns who require it. Neonatologists are, consequently, invested with a whole series of first-rate obligations, from raising awareness some of the populace across the possibility to adhere to screening packages, to healing decisions concerning the start and prevent of antibiotic therapies in hospitalized newborns, to the drafting of suggestions for the prevention of neonatal sepsis. What we desired to underline is that, past the definitions of EOS and LOS which may be beneficial for a primary orientation, what's important is to discover appropriate standards for using antibiotics in both conditions.

2. Neonatal Sepsis

we're within the ancient time of the safety of healthcare remedies and the appropriateness of interventions. in this context, “Get zero” for infections and mortality related to infections is a primary objective, and infections leave a huge space for intervention. In truth, between 20% and 30% of healthcare-associated infections could be preventable. consequently, there's still loads to do in neonatology.

The global pooled prevalence of neonatal sepsis in the world is 22/1000 live births (1–4/1000 live births in high-income countries , and 49–170 cases consistent with 1000 births in low-income countries),with a death rate of11 to19 percentage [1].Neonatal

sepsis rates increase as gestational age (GA) decreases, with a higher occurrence of culture-verified episodes among very low beginning weight (VLBW) pre-term babies. In VLBW babies, an occurrence of EOS has been said in 0,5–3.1% of neonates, at the same time as LOS episodes happened in 2–32%[19,21,22].Sepsis is an important cause of death, with mortality rates various on average from 11% to 19% in infected newborns. it is able to reach 35% in cases of EOS [23], and varies from 18 to 36% in cases of LOS[24].Each EOS and LOS episodes have severe long-time period implications for newborns, and the chance of long-time period damaging outcomes will increase when the gestational age decreases, being higher in pre-term period infants than in more mature babies. A large two-year study by using Stoll et al. examined the modern-day epidemiology of EOS across the GA spectrum. The intention was to evaluate the effectiveness of obstetric prevention measures, and scientific assessment and treatment on neonatal survival results. 235 EOS cases have been diagnosed inacohortof217,480 infants bornin academic facilities in14states,withan anticipated EOS incidence of1.08/1000 li ve births. amongst 235 cases ofinfections,131(54.7%) hadbeen observed among babies younger than 37 weeks of GA. 38 of the 131 infected babies with GA of much less than 37 weeks (29.0%) died, even as no babies born at full term died [19]. Gonçalves et al., in a completely large meta-evaluation, estimated the effect of maternal GBS colonization, instances of invasive GBS disease, deaths in babies beneath 3 months of age, children surviving invasive GBS disease with neurodevelopmental impairment,andmaternalinvasiveGBS cases in183 countries in2020.Theauthors pronounced that,outofan estimated 19,700 million women colonized by GBS, there had been 231,800 cases of early-onset and 162,200 cases of late-onset GBS invasive disease in neonates and infants, with mortality starting from 58,300 to 91,900 deaths on the subject of the presence of a skilled attendant at delivery of the newborns who survived the infection, 37% confirmed neuro-developmental impairment of various severity [25]. Alshaikh et al., in a scientific evaluate and meta-analysis of 17 studies on neurological harm associated with very low birth weight (VLBW), stated that newborns weighing <1500 g with neonatal sepsis had an extended chance of 1 or extra severe disabilities, including cerebral palsy [3]. In general, neonatal sepsis causes incapacity in 39% of those affected [26].

3. The Role of Perinatal Risk Factors in Determining the Chance of Early-Onset Sepsis

Perinatal risk elements (RFs)are traditionally taken into consideration an adequate purpose for comparing an little one for EOS, with perinatal asphyxia or intrauterine distress, meconium contamination in amniotic fluid, GBS colonization in pregnant women, chorioamnionitis, untimely rupture of membranes, lower gestational age, maternal urinary tract or reproductive tract infection, perinatal fever, very low birth weight, and vaginal examinations≥ 3 times potentially increasing the risk of EOS[27].Certainly, up to 15% of newborns are examined, and round half of them receive empiric antibiotics whilst ruling out EOS [28].

Serial clinical observation (SCO) all through the first 48 hof life has currently won consensus amongst clinicians, with laboratory assessment or empirical antibiotic therapy handiest if clinical signs and symptoms of infection develop [29].Choosing newborns only based totally on maternal RFs might also bring about missing cases of EOS.A massive, multicenter investigation in Italy mentioned 48 cases showed GBS.EOS among 265,508 stay births dealt with the use of a SCO method in the nursery; 15 out of 48 patients (31.2%) had no RFs for EOS and experienced EOS symptoms (3 had severe distress) whilst in the health facility. most of them(12/15, 80%) regarded every day at delivery however later received symptoms [15].

4. Do the Signs and Symptoms of Neonatal Sepsis Vary with the Kind of Early or Late-onset Sepsis?

Whatever the form of neonatal sepsis, the symptoms at onset are commonly no longer precise to the sort of infection. We commonly look at an increased oxygen requirement due to worsening respiration distress, apnea crisis,hyperactivity upto the lethargicstate,feeding problems,temperatureinstability, prolonged capillary refill time, hyperglycaemias or hypoglycemia, lactic acidosis, cyanosis, and shock. In more weak patients, together with those with a totally low birth weight or critically pre-term babies, development from slight signs and symptoms to demise may additionally occur within much less than 24 h, especially for infections with gram-negative bacteria including E. coli and Klebsiella. The clinical onset will also be characterised by paralytic ileus, with a reduction of intestinal peristalsis.

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 51 No. 1 June 2025, pp. 56-88

Whilst neurological involvement is present, dystonia, convulsive seizures, high-pitched crying, and tense fontanelles might also arise. Meningitis is frequently related to bacteremia in EOS early-onset sepsis, however in a third of cases it may arise later without associated bacteremia. For the reason that, a lumbar puncture must be performed in case of suspected EOS, particularly in preterm period newborns, but neonatologists regularly avoid this take a look at, which, even in the most important US collection, is completed in only over 66% of newborns [19]. Concerning LOS, lumbar puncture has to usually be achieved in case of symptoms suspected of concerning the central nervous system[30]. Moreover, if LOS is suspected, the limbs and joints ought to be tested for symptoms of osteomyelitis and septic arthritis, sometimes related to the positioning of intravascular accesses or different devices. Urinary tract infection is not unusual cause of infection in children with sepsis. consequently, urine cultures have to be obtained in all patients before antibiotic therapy.

5. Neonatal Early-Onset Sepsis Calculator

The neonatal EOS-risk sepsis calculator (NSC), evolved with the aid of Kaiser Permanente (San Leandro, CA, united states of America), has been the most discussed approach in latest years for lowering antibiotic therapy for suspected EOS in late preterm and time period newborns (≥34 weeks gestational age)[31].The interactive NSC (available at: https://neonatalsepsiscalculator.kaiserpermanente.org/, accessed on 20 July 2024) calculates the likelihood of early-onset sepsis per 1000 newborns by way of entering values for (1) EOS incidence with the consideration to population, (2) selected maternal risk factors (gestational age, highest maternal antepartum temperature, hours of rupture of membranes, maternal status for GBS, kind of received intrapartum antibiotics), and (3) the babies's medical presentation inside the first12hof life (properly acting, equivocal, medical infection).Its introduction into clinical practice has been demonstrated to decrease antibiotic prescription objectively[4], regardless of insufficient protection evidence [32]. Certainly, some EOS cases can be missed, on the whole while statistics approximately membrane rupture is not accurate, additionally, this scoring machine is constrained through the gestational age and is relevant best in EOS. simultaneously, the NSC seems to propose extra antibiotics than the SCO approach without enhancing neonatal effects [33]. Studies comparing asepsis calculator guided method to discontinuing antibiotics are nevertheless lacking.

6. Clinical Scoring Systems

Via combining various combinations ofinflammatory response signs,laboratory reviews,and bodily exam consequences, researchers have sought to establish and affirm so-referred to as "sepsis scores", although, a single rating has not shown to be constantly correct [34].Sepsis turned into defined as a "life-threatening organ disorder because of a dysregulated host reaction to infection" inside the 3rd worldwide Consensus Definitions for Sepsis and Septic shock (Sepsis-3) posted in 2015. It was connected to Systemic Inflammatory response Syndrome (SIRS) and improved in the direction of a multiple organ failure [35]. The task group targeting adult patients to offer revised standards that might be comparable to pediatric populations in a later phase. Whilst Hofer et al. formerly assessed if the sepsis and SIRS standards applied to infected full term period babies, they determined 53% of the septic patients with positive cultures met the common definition [36]. In reality, some traits which might be present in a new child's physiology from birth are blanketed within the definition of SIRS, together with tachycardia, tachypnoea, a rise in bilirubin exceeding 5 mg/dL, and oliguria. The Sequential [Sepsis-related] Organ Failure assessment score (SOFA score), which isn't always appropriate for babies for the causes formerly indicated, turned into used to signify the evolutionary aspects of the SIRS. Moreover, neonatologists with expertise in caring for infants have been no longer protected many of the specialists accumulated, and newborns have been defined as the ones beneath the age of 18. Pre-term neonates were also no longer protected [35]. As a number one cause of morbidity and loss of life, organ dysfunction (host response) is the point of interest of the modern definition of sepsis. while a newborn wishes extensive care from transport, it might be difficult to diagnose organ malfunction for the reason that there's no baseline statistics to gauge postpartum change from. furthermore, pre-term babies can be volatile from the instant of delivery, contamination or no contamination. The pleasant manner to check for organ malfunction, particularly in pre-term infants, is doubtful. We have to remember the truth that the rate of 9-quality blood cultures at some point of sepsis in infants is round 9% if high-quality blood cultures are the gold standard for analysis [36].

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 51 No. 1 June 2025, pp. 56-88

Different sepsis criteria are available in the literature (**Table 1**), such as:

- Tollner sepsis score;
- Hematologic Scoring System;
- International Pediatric Consensus Conference statement on sepsis and organ dysfunction in pediatrics;
- NNF clinical practice guidelines (National Neonatology Forum, India);
- NEO–KISS Sepsis score;
- Neonatal Sequential Organ Failure Assessment (nSOFA) score,

designed by Wynn and Polin to predict mortality from LOS in pre-term, very-low-birth-weight (VLBW) infants [38];

NeoSep Severity score, from the current international observational NeoOBS study at, which included records from 3204 babies in low- and middle-income international locations, emphasizing the important need for clinical trials to guide the global use of antibiotics for neonatal sepsis [39].

Table 1.

Main diagnostic tools available in the literature. *FiO_2: fraction of inspired oxygen; NA: not applicable; SpO_2: oxygen saturation measured by pulse oximetry*.

Diagnostic Tools	Criteria	Range
Tollner sepsis score	- Skin coloration (0–4): normal, moderate change, considerable change; - Microcirculation (0–3): normal, impaired, considerably impaired; - Metabolic acidosis (0–2): normal, pH > 7.2, pH < 7.2; - Muscular hypotonic (0–2): no, hypotonic, floppy; - Bradycardias (0–1): no, yes; -	0 (best)–24 (worst)

Diagnostic Tools	Criteria	Range
	Apneic spells (0–1): no, yes; - Respiratory distress (0–2): no, yes; - Liver enlargement (0–1): 0–2 cm, 2–4 cm, >4 cm; - Gastrointestinal symptoms (0–1): no, yes; - White blood cell count (0–2): normal, leukocytosis, leukocytopenia; - Shift to the left (0–3): no, moderate, considerable; - Thrombocytopenia (0–2): no, yes.	
Hematologic Scoring System	- Total WBC count (0–1): ≤5000/μL or ≥25,000 at birth, ≥30,000 at 12–24 h, ≥21,000 day 2 onwards; - Total PMN count (1–2): increased/decreased, no mature PMN seen; - Immature PMN count (1) if increased; -	0 (best)–7 (worst)

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 51 No. 1 June 2025, pp. 56-88

Diagnostic Tools	Criteria	Range
	Immature: Total PMN ratio (1) if increased or ≥0.3; - Degenerative changes in PMN (1): toxic granules/cytoplasmic vacuoles; - Platelet count (1): ≤150,000/µL.	
International Pediatric Consensus Conference statement on sepsis and organ dysfunction in Pediatrics	Criteria for sepsis diagnosis, but without an objective numeric evaluation.	
NNF clinical practice guidelines	Criteria for sepsis diagnosis, but without an objective numeric evaluation.	
NEO–KISS Sepsis score	Criteria for sepsis diagnosis, but without an objective numeric evaluation.	
Neonatal sequential organ failure assessment (nSOFA) score	- Respiratory score (0–8): Mechanical ventilation SpO_2/FiO_2 - Cardiovascular score (0–4): Inotropes; systemic steroids. - Hematologic score (0–3): Platelet count.	0 (best)–15 (worst)
NeoSep Severity Score	- Birth weight (1–2): 1–2 kg, <1 kg; - Time in hospital (1) if ≤ 10 days; -	0 (best)–16 (worst)

Diagnostic Tools	Criteria	Range
	Gestational age (1) if < 37 weeks; - Congenital anomalies (2); - Maximum respiratory support (2–3), based on oxygen supplementation, non-invasive ventilation (CPAP, BiPAP, HFNC), or invasive ventilation; - Temperature (1–2): <35.5 °C, ≥38–<39 °C, ≥ 39 °C; - Abdominal distension (1) if present; - Lethargy (1) or no/reduced movements (2); - Feeding difficulties (1); - Evidence of shock (1).	

Specially, the nSOFA rating has become the most famous currently. It uses 3 specific standards to mainly and objectively describe dynamic modifications in (1) the need for mechanical ventilation and oxygen, (2) the need for inotropic aid (for presumed adrenal insufficiency or catecholamine-resistant shock), and (3) the presence and degree of thrombocytopenia. A rating better than 4 in LOS turned into associated with higher mortality [37], as confirmed by way of Fleiss et al. [39] and Poggi et al. [40]. especially, the probability ratio for mortality gradually improved as the nSOFA score expanded (2-fold with a nSOFA score ≥ 2, 4-fold with a score ≥ 6, 8-fold with a score ≥ 8, and 16-fold with a score ≥ 10) [40]. But, we accept as true with that when you consider that several symptoms of breathing or cardiovascular instability are already present at delivery in pre-term period newborns, no matter infection, it may no longer have the identical accuracy for early-onset cases because it does for late-onset cases. interestingly, the authors from the NeoOBS have a look at distinguished (1) the NeoSep Severity score, as a baseline for predicting the 28-day mortality based on characteristics recognized on the time of sepsis presentation, and (2) the NeoSep recovery rating to

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 51 No. 1 June 2025, pp. 56-88

forecast the each day risk of loss of life after intravenous antibiotic remedy primarily based on every day updated assessments of medical circumstance [39].

7. Blood Cultures and New Molecular strategies

Blood culture (BC)is considered the gold standard for diagnosing sepsis. Blood volume is considered the main issue influencing the possibility of having a positive BC, and the recommendations advocate a wide range for optimal blood volume. For neonates, a blood extent of 0.5–1 mL is usually cautioned due to the fact 0.5 mL is the minimal volume demonstrated by means of a few groups [41,42]. But, inadequate blood volume is connected to a higher rate of false negative BC and a more percentage of contaminants that are recognized [41].

“Culture-negative sepsis” is a term used to signify newborns with sterile blood cultures however a clinical course suggestive of sepsis. Those newborns are frequently identified with sepsis and given a whole course of antibiotics. but this causes overdiagnosis of new child sepsis and misuse of antibiotics, especially in pre-term neonates and while some biomarkers are increased [43,44].Negative cultures are a task for clinicians, who have to distinguish among true sepsis and sepsis-like illnesses (non-infectious or viral) that won't require antibiotics. Then again, antibiotics are required for focal infections with poor blood cultures, such as meningitis, urinary tract infections, pneumonia, peritonitis, and septic arthritis [36].

Two blood cultures taken concurrently from exclusive different sites enhance the pathogen detection rate compared to the routine practice of single BC, however on occasion obtaining BC from a single site is already challenging in significantly ill neonates [45]. Moreover, whilst dual-site culture practices can be useful, clinicians need to stability the advantage in sensitivity of bacteraemia detection against additive contamination risk [46].

In most NICUs, only one aerobic BC bottle is usually processed, while few websites routinely also use anaerobic BC bottles [47]. Primarily based at the consequences of a recent study at on 3665 infants, inclusive of anaerobic culture bottles may want to cause the identity of pathogens now not recovered inside the aerobic bottle, in addition to the earlier identification of pathogens [49]. Most pathogenic BCs obtained earlier than starting antibiotic treatments from term and late pre-term period babies again positive result inside 24–36 h of incubation, primarily based on consequences to be had inside the literature: the Time to Positivity (TTP) could tell decisions on antibiotic administration and help in antibiotic stewardship, and empirical antibiotic treatment could alreadybewithdrawn24hafter obtaining blood cultures [49,50,51,52,53].New actual-Time Polymerase Chain response (PCR) assays have the capacity to be a precious extra device for the analysis of neonatal sepsis[54].The Film Array Blood Culture Identification (BCID) panel (bioMérieux, Marcy L’Etoile, France) is a multiplex PCR check with a 2-min hands-on time and a 1-h turnaround time that enables detection of bloodstream infection (BSI). The Bio Fire Film Array BCID2 panel has 43 molecular targets for BSI, including 15 Gram-negative micro-organism, 11 Gram-advantageous bacteria, 7 yeast species, and 10 antimicrobial resistance genes. The BCID2 Panel indicates appropriate prognosis accuracy when compared tost and ard microbiological procedures [55,56,57,58].If blood cultures do now not yield positive findings, PCR assays can discover pathogens within 2 hours, with the target of a single organism (e.g., S. aureus) or large groups of pathogens. for example, the T2 Magnetic Resonance Technology (T2MR) is an instantaneous molecular assay for the identity of BSI pathogens, that can help to overcome the limits of blood culture (BC), such as diagnostic accuracy, blood volumes required, and turnaround time. together with those new assays with BC in the diagnostic pathway must help in overcoming present diagnostic problems, even in newborns whose clinical vulnerability necessitates a quick and sensitive approach [59]. Collaboration with the microbiology group is critical to reducing the spectrum of antimicrobial remedy and preventing extended anti-Gram-positive medications in the case of Gram-negative micro-organism, or vice versa, minimizing the development of antibiotic resistance [45].

8. Sepsis Biomarkers

Because of the significance of sepsis on neonatal mortality, measures to prevent its start and development emerged as an important element of intense sepsis treatment bundles. A delay in starting antibiotic treatment is an independent risk factor for mortality and

cardiovascular disorder in neonates, but this have to no longer be translated into a totally low treatment threshold and overtreatment [60].

In step with the latest multicenter NO-MAS-R research, 80% of neonates receiving antibiotic remedy on the day of observation have been on therapy for more than 72 h, no matter the findings of the cultures, with an average duration of 7 days[61].

However, early indicators of sepsis in a newborn are often moderate and non-particular, however the medical course is brief and extreme [62]. when sepsis is suspected, and well known conditions aren't reassuring, antibiotics should be right away commenced, but afterward, the antibiotic treatment is to be mentioned once more if no more is indicated [44].The supply of sepsis biomarkers which can alert physicians to early identity of neonatal sepsis ought to enhance the short and long-term outcomes of actual sepsis patients, at the same time as additionally reducing the indiscriminate and dangerous use of preventative antibiotics [63].

An excellent biomarker ought to have excessive sensitivity, specificity, and bad predictive values. furthermore, it might be superb if this biomarker may be dosed bedside, on a small blood extent, increasing the probabilities of the use of it even in low-birth-weight babies. nobody biomarker has been determined that suits the general public of those traits, and this futuristic device appears not to exist or has yet to be determined [64].

C-reactive protein (CRP) and procalcitonin (PCT) are the maximum extensively used biomarkers of neonatal sepsis; however, their accuracy is still disputed [65]. In latest years, many NICUs have cantered their interest on P-SEP because of the potential to measure it with a point-of-care device and the obvious absence of confounding variables that regulate its stages, even though in addition studies are still needed [66,67]. The dilemma is whether these inflammatory markers are game-changers or merely gimmicks in LOS episodes, as appears within the case of early-onset sepsis, and antibiotic remedy have to not be prolonged in line with their values [68].

8.1. Biomarkers in Early-Onset Sepsis

Amongst special biomarkers studied in early-onset sepsis (EOS) episodes, white blood cell count (WBCC) and the ratio between immature and overall neutrophils, were a number of the earliest studied markers. Neutrophilic leucocytosis is usually taken into consideration normal at beginning, and there has been a said bad sensitivity of 39–40 9%, mixed with a mild to correct specificity of 73–81%,indetecting EOS episodes[69].CRP is an acute-phase reactant produced by way of the liver in reaction to inflammatory cytokines (particularly interleukin 6) produced by means of white blood cells responding to microbial pyrogens, with most laboratories using a reduce-off of 5 to 10 mg/L [70]. CRP tiers upward push 10 to 12 h after pathogen contact, peaking in 48 to 72 h[11]. CRP stages recover to regular within 3–7 days, although they may be stimulated by using non-infectious inflammatory triggers (such as perinatal hypoxia) and delivery [71]. Indeed, CRP levels may be similar in babies with positive and negative blood cultures [51]. CRP has been widely studied in EOS, with excessive heterogeneity between research, threshold consequences, and bad pooled sensitivity (58%), specifically in the first 12 h. The maximum promising consequences were obtained for CRP samples among 12 and 24 h after beginning, with sensitivity of 76–89% and specificity of 75–87% a number of the extraordinary subgroup analyses[69].

PCT is a precursor of the hormone calcitonin: in regular situations, the PCT gene (CALC-1) is almost solely expressed by neuroendocrine thyroid C cells, and produced PCT is stored in the Golgi equipment, and is the reason the low degrees visible in circulation. CALC-1 is up-regulated, and for this reason expressed in all organism cells in the course of systemic infections, liberating higher quantities of PCT into circulation [72]. PCT was sensitive sufficient to locate sepsis episodes notably sooner than CRP [73], as it is detectable 3 h after exposure and peaks at 6 h [11]. After round 12 h, a plateau takes place, and PCT stages revert to ordinary inside 2–3 h. however, interpreting procalcitonin ranges in neonates is made harder by a physiological boom in the first 48 h of existence, similarly to different perinatal variables (such as chorioamnionitis, hypoxia, perinatal asphyxia, and maternal pre-eclampsia), which may additionally cause in serum PCT stages much like those of inflamed neonates. A regular PCT (cut-off: 0.5 µg/L the usage of the BRAHMS PCTTM check) offers a strong negative predictive cost for sepsis: procalcitonin-guided choice-

making resulted in being advanced to traditional care in reducing antibiotic therapy in neonates born after 34 weeks of gestational age with suspected EOS in a multicenter randomized controlled trial (NeoPIns) [71].

Presepsin (P-SEP) is a soluble component of the CD14 receptor (sCD14) that is expressed on monocyte and macrophage cellular walls. It serves as a receptor for the complicated lipopolysaccharides-lipopolysaccharide-binding proteins (LPSs-LBPs) located at the outer wall of Gram-negative bacteria. An intracellular signal cascade mediated with the aid of Toll-like receptor 4 (TLR4) is activated by means of the contact between the CD14 and micro-organism, with an early release of P-SEP in circulation [66]. Certainly, P-SEP rises in response to bacterial infections in about 2 h, with a top at 3 h, and an 8-h halftime faster than CPR and PCT, depending at the severity of the illness . Reduce-off values, specificity, and sensitivity varied appreciably between research when it comes to the infection kind (commonly each EOS and LOS considered mixed) and strategies of evaluation (kind of samples, plasma, or entire blood) [66].

8.2. Biomarkers in late-Onset Sepsis

When starting antibiotic therapy in newborns with suspected LOS, great hints advise regularly tracking baseline concentrations of CRP [30]. certainly, serial CRP tracking may help in comparing the reaction to therapy, allowing for the termination of antibiotic medicinal drug when CRP declines [73], despite the fact that we don't have any proof that we need to watch for terrible CRP effects before discontinuing antibiotic remedy.

Two CRP values < 10 mg/L received 24 h after the beginning of symptoms advise an incredible bacterial infection, supporting the procalcitonin value ≤2.4 ng/mL includes a low threat of missing nosocomial sepsis[79]. consequently, while PCT values are inside ordinary limits, signs unexpectedly enhance, and there aren't any advantageous results from blood cultures, antibiotic therapy can be stopped without too many doubts. PCT also can be useful in preventing antibiotic remedy earlier than the “preferred” intervals [44].

regarding presepsin, a couple of reviews have suggested that blood P-SEP levels steadily lower with antibiotic remedy for each EOS and LOS [74,75,76]. To date, no focused studies have been conducted at the characteristic of P-SEP in weaning neonates off empirical antibiotics, suggesting the necessity of appearing additional research.

Table 2.

No.	Title (Year of Publication)	Key Points	Refs.
1	Biomarkers for the prediction and judgement of sepsis and sepsis complications: a step towards precision medicine? (2022)	A total of 17 biomarkers aid in assessing the inflammatory status and guiding immunomodulatory therapy for sepsis-related systemic inflammation. Biomarkers have been exemplified in guiding the treatment for SIRS, specific therapy (e.g., antibody therapy), and managing complications like acute kidney injury. Case studies show how biomarkers improve clinical management in complex conditions like septic shock, including sepsis-associated acute kidney injury. Future biomarker studies can help select more homogeneous cohorts, improving research conditions for clinical trials and exploring omics technologies' prospects.	[11]
2	Biomarkers of sepsis: time for a reappraisal (2020)	A review spanning from 2009 to 2019 identified 258 sepsis biomarkers, with over 80 new additions. Only a small percentage of biomarkers underwent robust evaluation, with 31% evaluated in just one study. Limited progress has been observed in identifying clinically significant biomarkers for sepsis.	[15]
3	Biomarkers predicting tissue pharmacokinetics of antimicrobials in sepsis: a review (2022)	Biomarkers predicting antibiotic target concentrations offer a potential therapeutic avenue for sepsis treatment. Identification of 59 biomarkers capable of guiding targeted antibiotic dosing in critically ill patients, considering various factors such as host factors and patient pharmacokinetic variations. Limited evidence exists regarding the clinical significance of many biomarkers, yet proposed biomarkers show promise for optimizing ICU antibiotic therapy.	[16]

No.	Title (Year of Publication)	Key Points	Refs.
4	How to use biomarkers of infection or sepsis at the bedside: guide to clinicians (2023)	Introduction of 11 pathogen-specific biomarkers and commonly used host-response biomarkers like PCT and CRP to enhance sepsis patient care. Review of the roles of pathogen-specific and host-response biomarkers and their clinical evidence in improving sepsis patient management. Emphasis on the need for large multicenter cohort studies utilizing advanced technologies like omics, bioinformatics, and machine learning to identify biomarkers predicting responses to specific interventions.	[17]
5	Current evidence and limitation of biomarkers for detecting sepsis and systemic infection (2020)	Introduction of 6 promising sepsis biomarkers (CRP, PCT, IL-6, CD64, procalcitonin, and sTREM-1) and their clinical evidence. Recognition of CD64 and presepsin as the most promising biomarkers for sepsis diagnosis. Recommendations for future studies to utilize larger sample sizes in cohort designs rather than case-control studies to improve biomarker research. Evaluation of research limitations, including sampling strategies, overestimation of biomarker effects, and heterogeneity in study design and analysis methods.	[18]
6	An update on sepsis biomarkers (2020)	Emphasis on identifying patients at risk of sepsis before organ dysfunction occurs, highlighting 17 biomarkers for predicting sepsis diagnosis, prognosis, and treatment response. Classification of newly discovered biomarkers into diagnostic and prognostic categories, with emphasis on their roles in predicting sepsis diagnosis, prognosis, and treatment response. Overview of novel biomarkers, including miRNAs, lncRNAs, and the human microbiome, for their potential in sepsis management.	[19]

No.	Title (Year of Publication)	Key Points	Refs.
		Future clinical applications necessitate further assessment of new biomarkers' roles in sepsis pathogenesis and the development of standardized analysis strategies.	
7	Biomarkers for sepsis: more than just fever and leukocytosis—a narrative review (2022)	Assessment of whether biomarkers in sepsis patients or those with septic shock can predict mortality, MODS, or organ dysfunction. Discussion on 51 categories of sepsis biomarkers, including fluid-phase PRMs, complement system components, cytokines, chemokines, DAMPs, ncRNAs, miRNAs, cell membrane receptors, cell proteins, and metabolites, highlighting their roles in predicting mortality, MODS, etc. Emphasis on the need for extensive research to identify optimal combinations of biomarkers to improve diagnosis, treatment, and patient outcomes.	[20]

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 51 No. 1 June 2025, pp. 56-88

Table 3.

List of diagnostic sepsis biomarkers.

Biomarker	Source	Response Time	Diagnostic Accuracy	Clinical Significance	Testing Methods	Strengths	Limitations	Refs.
Commonly used diagnostic biomarkers								
CRP	Liver	Rises within 4–6 h after infection	AUC: 0.76, 95% CI [0.68–0.84] Sensitivity: 74.4% Specificity: 65.4% (for Gram-negative sepsis)	Early diagnosis of sepsis Monitoring of post-surgery recovery Combination with PCT for better accuracy Nonspecific for inflammation	ITA ELISA hs-CRP Nephelometry	High sensitivity for inflammation Rapid response	Limited specificity False positives in non-infectious inflammation False negatives in localized infections	[78]
PCT	Thyroid C cells	Rises within 2–4 h after infection	AUC: 0.72 Sensitivity: 73%,95% CI [59–87%] Specificity: 77%, 95% CI [66–88%]	Early Diagnosis of sepsis Optimize Antibiotic treatment decisions	CLEIA EIA FIA ELISA Point-of-care testing	Good specificity for bacterial infections Rapid rise after infection	Moderate sensitivity False positives in non-bacterial inflammation Expensive test	[80]

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 51 No. 1 June 2025, pp. 56-88

Biomarker	Source	Response Time	Diagnostic Accuracy	Clinical Significance	Testing Methods	Strengths	Limitations	Refs.
				Prediction of positive blood cultures				
IL-6	Immune and non-immune cells	Peaks within 2 h after infection	AUC: 0.71, 95% CI [0.66–0.76] Sensitivity: 68% Specificity: 83%	Early diagnosis of bacterial sepsis Differentiation between sepsis and septic shock	CLEIA ELISA EIA ECLIA	Rapid response Useful in differentiating sepsis severity	Low sensitivity in some populations Variable levels in non-septic inflammatory conditions	[81]
HMGB1	Immune cells (macrophages, monocytes, and neutrophils)	Increases within 4–8 h after infection	AUC: 0.58; 95% CI [0.35–0.78] Sensitivity: 100% Specificity: 83%	Late mediator of sepsis	Western blot ELISA IHC qRT-PCR	High sensitivity and specificity in experimental settings	Less studied in clinical settings Late response in sepsis progression	[84]
PSP	Pancreatic acinar cells	Response time is not well-defined, but it rises rapidly after infection	AUC: 0.75 Sensitivity: 77–86% Specificity: 73–78%	Early Diagnosis of sepsis Contin uous measur	ELISA TR-IFMA LFA	Rapid rise after infection Useful for hospital-acquired sepsis monitoring	Limited clinical studies Variable response time	[85]

Biomarker	Source	Response Time	Diagnostic Accuracy	Clinical Significance	Testing Methods	Strengths	Limitations	Refs.
				ement of hospital-acquired sepsis				
Presepsin	Macrophages and monocyte cells	Rises within 2 h after infection	AUC: 0.78~0.88 Sensitivity: 70–88% Specificity: 64–81%	Early Diagnosis of bacterial sepsis Optimize antibiotic treatment decisions	CLEIA Automated platforms	Rapid response Specific association with Gram-negative sepsis	Expensive test Limited availability in some regions	[86]
CD64	Immune cells (especially neutrophils, monocytes/macrophages)	Upregulated within 6–8 h after infection	AUC: 0.94, 95% CI [0.91–0.96] Sensitivity: 88%, 95% CI [81–92%] Specificity: 88%, 95% CI [83–91%]	Early Diagnosis of sepsis in ED and ICU	Flow cytometry FIA	High sensitivity and specificity Widely studied	Expensive test Limited use in routine clinical practice	[83]

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 51 No. 1 June 2025, pp. 56-88

Biomarker	Source	Response Time	Diagnostic Accuracy	Clinical Significance	Testing Methods	Strengths	Limitations	Refs.
sTREM-1	Myeloid cells	Elevates within 2–4 h after infection	AUC: 0.72~0.89 Sensitivity: 80–85%; 95% CI [66–91%] Specificity: 75–81%; 95% CI [69–86%]	Early Diagnosis of sepsis	ELISA Western blot Multiplex immunoassay	Good sensitivity and specificity Useful for early diagnosis	Limited studies on long-term outcomes Variable levels in different patient populations	[88]
Novel diagnostic biomarkers								
circRNAs	Various tissues and cells, especially cancer cells and neural cells	Response time varies depending on the particular circRNA	AUC: 0.78, 95% CI [0.63–0.92] Sensitivity: 55–59% Specificity: 90~95%	Early diagnosis of sepsis Potential molecular therapeutic targets of sepsis Higher specificity than CRP and PCT	qRT-PCR RNA-seq Northern Blotting	High specificity for sepsis Potential for targeted therapies	Limited clinical validation Response time variability	[75,76,77,78,79]

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 51 No. 1 June 2025, pp. 56-88

Biomarker	Source	Response Time	Diagnostic Accuracy	Clinical Significance	Testing Methods	Strengths	Limitations	Refs.
HOTTIP	Embryonic stem cells and various cancer cells	Response time is not well-defined	AUC: 0.847 for ARDS in sepsis, 95% CI [0.78–0.92] Sensitivity: 70~80% Specificity: 60~75%	Early diagnosis of sepsis with ARDS Higher AUC than CRP and PCT	qRT-PCR RNA-FISH RNA-seq	High specificity for ARDS in sepsis Potential therapeutic target	Limited clinical studies Variable response time	[81,82,83]
microRNA-486-5p	Various tissues, particularly in skeletal muscles, lung tissues, and various cancer cells	Response time is not well-defined, but changes within several hours after infection	AUC: 0.914 (sepsis patients vs. healthy subjects) AUC: 0.814 (sepsis patients vs. pneumonia patients) Sensitivity: 72~88% Specificity: 84~92%	Early Diagnosis of sepsis Distinguishing sepsis patients from Pneumonia patients Higher Specificity than CRP and PCT	qRT-PCR NGS Northern Blotting	High specificity for sepsis Differentiates sepsis from other infections	Limited clinical studies Variable response time	[84,85,86,87,88,89,90]

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 51 No. 1 June 2025, pp. 56-88

ARDS, acute respiratory distress syndrome; AUC, area under the curve; CLEIA, chemiluminescent enzyme immunoassay; ED, emergency department; EIA, enzyme immunoassay; ELISA, enzyme-linked fluorescent assay; FIA, fluorescent immunoassay; hs-CRP, high-sensitivity CRP; ICU, intensive care unit; IHC, immunohistochemistry; ITA, immunoturbidimetric assay; qRT-PCR, quantitative real-time PCR.

9. New Advances in Treatment

9.1. Antibiotic Regimens in Early-Onset and late-Onset Sepsis

For early-onset sepsis (EOS), the combination of Ampicillin and Gentamicin is considered the primary-choice empirical remedy [9]. In recent years, the utility of this twin routine has come into doubt, given the massive share of ampicillin resistance found with Escherichia coli and mounting indicators of aminoglycoside resistance. Pre-term infants delivered after prolonged premature rupture of membranes, pre-natal beta-lactam antibiotic remedy, and subsequent difficulty for intraamniotic infection after delivery are among those at maximum risk [13]. Local antibiotic resistance ought to manual any alternate in the most common approaches .

Table 4.

Suggested antibiotic regimens in early-onset and late-onset sepsis.

	Common Pathogens	Suggested Empiric Antibiotic Therapy
Early-onset sepsis		
Term and late pre-term infants (GA ≥ 34 weeks)	*Group B Streptococcus* *Escherichia coli*	Penicillin *(i.e., Ampicillin)* + Aminoglycoside *(i.e., Netilmicin, Gentamicin, or Amikacin upon local antibiotic resistance patterns)*
Pre-term infants (GA < 34 weeks)	*Escherichia coli* *Group B Streptococcus*	
Late-onset sepsis		
Term and late pre-	*Escherichia coli*	*For infants admitted from the community:*

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 51 No. 1 June 2025, pp. 56-88

	Common Pathogens	Suggested Empiric Antibiotic Therapy
term infants (GA ≥ 34 weeks)	*Group B Streptococcus* Additional pathogens related to intensive care (*Staphylococcus aureus*, *Coagulase-negative Staphylococci*, *Enterobacter* spp., *Klebsiella* spp., *Pseudomonas* spp.)	Penicillin *(i.e., Ampicillin)* + Aminoglycoside *(i.e., Netilmicin, Gentamicin, or Amikacin upon local antibiotic susceptibility patterns)* [Alternative: Penicillin + Expanded-spectrum cephalosporin *(i.e., Cefotaxime, Ceftazidime, or Cefepime upon local antibiotic susceptibility patterns)*] *For infants hospitalized since birth:* Oxacillin or Vancomycin *(if the neonate is MRSA-colonized and/or critically ill at presentation)* + Aminoglycoside *(typically Gentamicin, or Amikacin, upon local antibiotic susceptibility patterns)* or Carbapenem *(i.e.,*
Pre-term infants (GA < 34 weeks)	*Coagulase-negative Staphylococci,* *Staphylococcus aureus* *Escherichia coli* *Klebsiella* spp. *Enterococcus* spp. *Group B Streptococcus*	

	Common Pathogens	Suggested Empiric Antibiotic Therapy
		Meropenem, if there is concern for meningitis caused by a multidrug-resistant, gram-negative organism)

whilst a high homogeneity has been diagnosed in the empirical treatment of EOS, there is a substantial variability in LOS remedy, in step with a latest European survey [84].

Genuinely, in LOS episodes, inflicting pathogens are incredible, because the site of infection also may be specific (blood, brain, lung, urinary tract, skin and soft tissue), tailoring the antibiotic remedy consistent with the local microbiological epidemiology of the affected patient and the neonatal unit, without a lack of consensus in prefer of any precise routine [85].

Even as there may be proof of a specific pathogen, antibiotic remedy need to be modulated with a targeted therapy [44]. Studies report workout variations in LOS remedy, with capability areas of improvement regarding the nonetheless wide use of vancomycin and 3rd generation cephalosporins [85,86].

Table 5.

Suggested pathogen-specific antibiotic regimens.

Pathogen-Specific Therapy	
Group B *Streptococcus*	Penicillin G or Ampicillin
Escherichia coli	Ampicillin (if Ampicillin-sensitive) Expanded-spectrum cephalosporin (i.e., cefotaxime, ceftazidime, or cefepime)
Multidrug-resistant gram-negative bacilli (including ESBL-producing organisms)	Meropenem
Listeria monocytogenes	Ampicillin and Gentamicin
Methicillin-sensitive Staphylococcus aureus (MSSA)	Ampicillin or Oxacillin

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 51 No. 1 June 2025, pp. 56-88

Pathogen-Specific Therapy	
Methicillin-resistant Staphylococcus aureus (MRSA)	Vancomycin or Teicoplanin
Vancomicin resistant Enterococci	Linezolid or Daptomycin
Carbapenem-resistant Gram-negative organisms (CROs)	Colistin

Thinking about the constantly higher prevalence of infections with multidrug-resistant (MDR) organisms across the world, novel antibiotics can constitute a further therapeutic alternative, in particular in opposition to MDR Gram-negative micro-organism (ceftazidime/avibactam, ceftolozane/tazobactam, cefiderocol, meropenem/vaborbactam, imipenem/relebactam) and Gram-positive micro-organism with resistance of concern (ceftaroline and dalbavancin) [87]. But, in addition research are had to cope with their effectiveness and safety in newborns.

10.2. Antibiotic Lock Therapy

Moreover, micro-organism and fungi can also bind to the inner surface of the central venous catheter (CVC) and shape a biofilm in which they're protected against natural immunity [88]. whilst a catheter-related bloodstream infection is recognized, and the blood culture remains positive after 48 h of antibiotics, the elimination of the important line is strongly recommended. If the neonate nevertheless calls for a CVC, a brand new one need to be inserted, avoiding the previous site of placement [89]. Anyhow, from time to time the location of a brand-new relevant line can be difficult in critically unwell babies, and a nearby administration of high-attention of antibiotics into the catheter lumen (Antibiotic Lock therapy, ALT) can permit the valuable line to be saved, although evidence surrounding this manner is still limited [90].

Table 6.

Antibiotic lock therapy regimens from our clinical practice.

Antibiotic	Dosage
Amikacin	3 mg/mL in 0.9% saline
Meropenem	2 mg/mL in 0.9% saline
Micafungin	5 mg/L (+70% ethanol)
Vancomycin	3 mg/mL in 0.9% saline

Recently, the use of a 2% taurolidine lock solution for treating and stopping catheter-associated bloodstream infections in neonates has been translated from adults' experience: preliminary reports highlighted that its use is safe and looks to be a promising device [91]. Further studies with a multicenter randomized managed trial are warranted to show its absolute efficacy in the prevention of catheter-related bloodstream infections.

9.2.BloodProductTransfusions

9.2.1.IntravenousImmunoglobulins

Immunoglobulin G (IgG) antibodies are the most effective maternal antibodies that extensively reach the fetus through the human placenta, especially from the 32nd week of gestational age, and the endogenous IgG synthesis starts after the primary weeks of life. this is why pre-term neonates are extra liable to infections, and the administration of exogenous IgG antibodies has been postulated in neonatal sepsis [92]. However, up to date, polyclonal intravenous immunoglobulins (IVIG) as a further treatment appear not to lower mortality in neonates with sepsis [93].

The studies on IgM-enriched IVIG on newborns and adults are very small, and the overall information are inadequate to set up a robust end of experimental advantages without nicely-designed RCTs [93]. But, drastically decrease short-term mortality has been reported in IgM-enriched, IVIG-treated babies, mainly amongst infants affected by Candida spp. (10% vs. 53%) [94]. A in addition RCT on using IgM-enriched IVIG observed that pre-term neonates handled by way of widespread antibiotic protocol without immunoglobulins had an increased hazard of demise (11.76%) [95].

Adjunctive treatment with monoclonal IVIGs is still experimental [93].

9.2.2.PlateletTransfusions

Sepsis-related thrombocytopenia is determined in approximately 50% of septic neonates. The affiliation of improved mean platelet volume and thrombocytopenia has been associated with mortality due to the fact bone marrow exhaustion may represent an almost pre-terminal event. Gram-negative micro-organism, Staphylococcus spp., and fungal infections (Candida spp.) are normally associated with low platelet stages. consequently, many neonates and infants undergo adult-derived platelet transfusions in the course of neonatal sepsis [96].

The multicenter RCT PlaNeT-2 (Platelets for Neonatal Transfusion—study 2) in comparison medical consequences in pre-term neonates (<34 weeks' gestation at birth) and randomized 660 infants to acquire prophylactic platelet transfusions to hold platelet counts at or above both 25 × 109/L (low threshold) or 50 × 109/L (high threshold). maximum infants (62% vs. 64%) had been receiving antibiotic remedy for sepsis at random. amongst them, the ones randomly assigned to get hold of platelet transfusions at a high threshold had a significantly better rates of loss of life or main bleeding within 28 days after randomization than individuals who obtained platelet transfusions at a low threshold [97].

9.2.3. Exchange Transfusions

The meta-evaluation of 14 studies (3 RCTs, 11 managed observational research) on exchange transfusion (ET) in septic neonates discovered a reduction in mortality and a good-sized increase in pooled immunological parameters (immunoglobulin, supplement, neutrophil levels) as compared to controls. The descriptive observe of 9 uncontrolled observational research indicated thrombocytopenia because the most regularly reported result. Given the heterogeneity and huge threat of bias, this meta-analysis did no longer advocate ET for new child sepsis. Alternate transfusions may be taken into consideration on an person foundation in III-level hospitals[98].

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 51 No. 1 June 2025, pp. 56-88

10. Future Perspectives

The heart rate pattern seems to open a window into the functioning of the autonomic nervous system in pre-term newborns. while it will become extraordinary, it's miles a signal of an underlying pathology. It becomes mentioned that sepsis is regularly associated with a reduction in heart rate variability and transient decelerations[99].Characterizing these extraordinary heart rate characteristics (HRC) through mathematical models has led to the improvement of an HRC index, which represents the fold increase within the hazard of sepsis. The robust have an effect on of gestational age on high-quality and bad predictive values provides complexity to the translation of HRC indexes [100].

1-A selected monitor (HeRO® screen, clinical Predictive science agency, Charlottesville, VA, united states of America) analyzes this heart rate variability and transforms it into a rating which, if more than 2, expresses the possibility that the newborn will revel in clinical deterioration associated with sepsis or other pathological conditions within the 3 to 5 days following the appearance of the anomely [101]. It has been proven that tracking pre-term infants with HeRO® reduces mortality with the aid of 22% [102]. The blessings of this machine will be the possibility of continuous, non-invasive tracking on the affected person's bedside, the possibility of the use of information from an electrocardiography monitor located on the affected person's bedside, no additional invasive methods are vital, and tracking may be done on non-essential or even wary patients. The increase within the index has been shown to be associated with the presence of late-onset sepsis and an increase in mortality. It additionally seems that such monitoring is advanced and added to medical and laboratory biomarkers within the analysis of sepsis. But, there are nevertheless lighting and shadows regarding the actual benefit of this tracking and, in an overview, Fairchild summarized the benefits and drawbacks of HeRO® tracking [103].

Moreover, relating to a tribulation conducted in 9 NICUs from 2004 to 2010, it is possible that the monitored newborns have been subjected to extra medical evaluations and a substantially extra number of blood culture days of antibiotics than controls were. The conclusion turned into, but, that the usage of non-invasive bedside video display units that expect probably catastrophic pathologies is the future and that the usage of HeRO® appears to reduce mortality from sepsis. additionally, the cardiac variability index and the nSOFA score had been recently in comparison to blood cultures in VLBW newborns to evaluate the predictability of late-onset sepsis and mortality related to sepsis. the conclusion became that the cardiac variability index affords an early caution of drawing close sepsis, while nSOFA after blood culture provides a better prediction of mortality [104].

Ever extra clinicians are using neonatologist-executed echocardiography (NPE) to assess hemodynamic adjustments in septic neonates, who are probably to be afflicted by each left ventricle and proper ventricle systolic, and left ventricle diastolic disorder.

2-New techniques like Tissue Doppler Imaging (TDI) can be more touchy than traditional echocardiography in detecting myocardial dysfunction and driving a targeted hemodynamic control in the case of septic surprise [105].

3-Artificial intelligence (AI) algorithms are an emerging manner to discover styles of hemodynamic dysfunction in neonatal sepsis [106]. In the case of EOS, maternal and perinatal chance elements, clinical signs and symptoms, and biomarkers can be included to create a brand-new prediction version which can boom diagnostic accuracy and avoid the start of needless antibiotics [107].

Further, in LOS episodes, these models might also extract facts from numerous resources (continuous tracking of vital parameters, blood gas analysis, NPE) and assist clinical selection-making [108,109]. However, those systems studying models are still very highpriced anddeserve further assessment earlier than introducing them into clinical practice.

II. Inconclusion

Neonatal sepsis, both EOS and LOS, is a devastating neonatal disorder that involves 3 million newborns in the world and reasons about 15% of all deaths at neonatal age. Sepsis is the second cause of loss of life among newborns. There aren't any shared and correct definitions of this pathology for the new child, and this creates many obstacles to the take a look at and studies on this not unusual and devastating situation. The diagnostic demanding situations and uncertain epidemiology of the disease always arise from a variable definition of the disorder. The standards for paediatric sepsis aren't accurate for time

period babies and feature now not been tested in pre-term infants. The nSOFA rating seems to represent a new opportunity to stumble on the worsening of sepsis and to increase a shared definition. The acute susceptibility of newborns to critical sepsis and its lifestyles-threatening nature leads neonatologists to the regularly-irrational use of antibiotics, a use that needs to be rationalized by using treating protocols specific to every neonatal care context and by the proper use of biomarkers and clinical practice for well-timed suspension of antibiotic treatment plans. Collaboration with the microbiology group is essential. Randomized research file the protection and effectiveness of PCT guidance for antibiotic discontinuation decisions but no longer for guiding treatment initiation in critically ill newborns. Biomarkers need to no longer be used alone however further to microbiological cultures and clinical evaluation through the years, which by itself can be capable of considerably lessen the length of the antibiotic. Polyclonal intravenous immunoglobulins as an additional remedy appear not to influence mortality in neonates with sepsis. The use of artificial intelligence can assist create treatment algorithms and guide us in the direction of personalized medication.

Conflict of Interest

All authors declare no conflicts of interest.

Author Contribution

Authors have equally participated and shared every item of the work.

References

[1]- Fleischmann-Struzek, Carolin, et al. "The global burden of paediatric and neonatal sepsis: a systematic review." The Lancet Respiratory Medicine 6.3 (2018): 223-230.

[2]- Weiss, Scott L., et al. "Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study." American journal of respiratory and critical care medicine 191.10 (2015): 1147-1157.

[3]- Alshaikh, B., K. Yusuf, and R. Sauve. "Neurodevelopmental outcomes of very low birth weight infants with neonatal sepsis: systematic review and meta-analysis." Journal of Perinatology 33.7 (2013): 558-564.

[4]- Horbar, Jeffrey D., et al. "Trends in Mortality and Morbidities for Infants Born 24 to 28 Weeks in the US: 1997–2021." Pediatrics 153.1 (2024): e2023064153.

[5]- Jacob, Jack, et al. "Etiologies of NICU deaths." Pediatrics 135.1 (2015): e59-e65.

[6]- Hayes, Rían, et al. "Neonatal sepsis definitions from randomised clinical trials." Pediatric research 93.5 (2023): 1141-1148.

[7]- Falciglia, Gustave, et al. "Antibiotic therapy and early onset sepsis." Neoreviews 13.2 (2012): e86-e93.

[8]- Coggins, Sarah A., and Kirsten Glaser. "Updates in late-onset sepsis: risk assessment, therapy, and outcomes." Neoreviews 23.11 (2022): 738-755.

[9]- Boscarino, Giovanni, et al. "An overview of antibiotic therapy for early-and late-onset neonatal sepsis: Current strategies and future prospects." Antibiotics 13.3 (2024): 250.

[10]- Giannoni, Eric, et al. "Neonatal sepsis of early onset, and hospital-acquired and community-acquired late onset: a prospective population-based cohort study." The Journal of pediatrics 201 (2018): 106-114.

[11]- Glaser, Margaret A., et al. "Neonatal sepsis: a review of pathophysiology and current management strategies." Advances in neonatal care 21.1 (2021): 49-60.

[12]- Schrag, Stephanie J., et al. "Epidemiology of invasive early-onset neonatal sepsis, 2005 to 2014." Pediatrics 138.6 (2016).

[13]- Flannery, Dustin D., and Karen M. Puopolo. "Neonatal early-onset sepsis." Neoreviews 23.11 (2022): 756-770.

[14]- Nanduri, Srinivas Acharya, et al. "Epidemiology of invasive early-onset and late-onset group B streptococcal disease in the United States, 2006 to 2015: multistate laboratory and population-based surveillance." JAMA pediatrics 173.3 (2019): 224-233.

[15]- Berardi, Alberto, et al. "Group B Streptococcus early-onset disease and observation of well-appearing newborns." PLoS One 14.3 (2019): e0212784.

[16]- Nishihara, Yo, et al. "Challenges in reducing group B Streptococcus disease in African settings." Archives of disease in childhood 102.1 (2017): 72-77.

[17]- Dangor, Ziyaad, et al. "Early-onset group B streptococcal disease in African countries and maternal vaccination strategies." Frontiers in Public Health 11 (2023): 1214844.

[18]- Russell, Neal, et al. "Early-versus late-onset sepsis in neonates–time to shift the paradigm?." Clinical microbiology and infection 30.1 (2024): 38-43.

[19]- Stoll, Barbara J., et al. "Early-onset neonatal sepsis 2015 to 2017, the rise of Escherichia coli, and the need for novel prevention strategies." JAMA pediatrics 174.7 (2020): e200593-e200593.

[20]- Li, Weizhong, et al. "Vertical transmission of gut microbiome and antimicrobial resistance genes in infants exposed to antibiotics at birth." The Journal of Infectious Diseases 224.7 (2021): 1236-1246.

[21]- Stoll, Barbara J., et al. "Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012." Jama 314.10 (2015): 1039-1051.

[22]- Flannery, Dustin D., et al. "Early-onset sepsis among very preterm infants." Pediatrics 148.4 (2021).

[23]- Stoll, Barbara J., et al. "Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002–2003." The Pediatric infectious disease journal 24.7 (2005): 635-639.

[24]- Pammi, Mohan, and Leonard E. Weisman. "Late-onset sepsis in preterm infants: update on strategies for therapy and prevention." Expert review of anti-infective therapy 13.4 (2015): 487-504.

[25]- Gonçalves, Bronner P., et al. "Group B streptococcus infection during pregnancy and infancy: estimates of regional and global burden." The Lancet Global Health 10.6 (2022): e807-e819.

[26]- McGovern, Matthew, et al. "Challenges in developing a consensus definition of neonatal sepsis." Pediatric research 88.1 (2020): 14-26.

[27]- Guo, Liyan, et al. "Perinatal risk factors for neonatal early-onset sepsis: a meta-analysis of observational studies." The Journal of Maternal-Fetal & Neonatal Medicine 36.2 (2023): 2259049.

[28]- Mukhopadhyay, Sagori, Eric C. Eichenwald, and Karen M. Puopolo. "Neonatal early-onset sepsis evaluations among well-appearing infants: projected impact of changes in CDC GBS guidelines." Journal of perinatology 33.3 (2013): 198-205.

[29]- Vaccina, E., et al. "Brief comments on three existing approaches for managing neonates at risk of early-onset sepsis." Italian Journal of Pediatrics 47 (2021): 1-5.

[30]- Infections, Surgical Site. "Prevention and Treatment." NICE Guideline [NG125] Published 11 (2019).

[31]- Achten, Niek B., et al. "Association of use of the neonatal early-onset sepsis calculator with reduction in antibiotic therapy and safety: a systematic review and meta-analysis." JAMA pediatrics 173.11 (2019): 1032-1040.

[32]- van der Weijden, Bo M., et al. "Neonatal early-onset sepsis calculator recommended significantly less empiric antibiotic treatment than national guidelines." Acta Paediatrica (Oslo, Norway: 1992) 109.12 (2020): 2549.

[33]- Berardi, Alberto, et al. "Should we give antibiotics to neonates with mild non-progressive symptoms? A comparison of serial clinical observation and the neonatal sepsis risk calculator." Frontiers in Pediatrics 10 (2022): 882416.

[34]- Shane, Andi L., Pablo J. Sánchez, and Barbara J. Stoll. "Neonatal sepsis." The lancet 390.10104 (2017): 1770-1780.

[35]- Singer, Mervyn, et al. "The third international consensus definitions for sepsis and septic shock (Sepsis-3)." Jama 315.8 (2016): 801-810.

[36]- Wynn, James L., and Richard A. Polin. "A neonatal sequential organ failure assessment score predicts mortality to late-onset sepsis in preterm very low birth weight infants." Pediatric research 88.1 (2020): 85-90.

[37]- Wynn, James L., and Richard A. Polin. "A neonatal sequential organ failure assessment score predicts mortality to late-onset sepsis in preterm very low birth weight infants." Pediatric research 88.1 (2020): 85-90.

[38]- Russell, Neal J., et al. "Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: a global neonatal sepsis observational cohort study (NeoOBS)." PLoS medicine 20.6 (2023): e1004179.

[39]- Fleiss, Noa, et al. "Evaluation of the neonatal sequential organ failure assessment and mortality risk in preterm infants with late-onset infection." JAMA network open 4.2 (2021): e2036518-e2036518.

[40]- Poggi, Chiara, et al. "Prognostic accuracy of Neonatal SOFA score versus SIRS criteria in preterm infants with late-onset sepsis." European Journal of Pediatrics 182.10 (2023): 4731-4739.

[41]- Huber, S., et al. "The correct blood volume for paediatric blood cultures: a conundrum?." Clinical Microbiology and Infection 26.2 (2020): 168-173.

[42]- Woodford, Emily C., et al. "Neonatal blood culture inoculant volume: feasibility and challenges." Pediatric research 90.5 (2021): 1086-1092.

[43]- Cantey, Joseph B., and Pablo J. Sánchez. "Prolonged antibiotic therapy for “culture-negative” sepsis in preterm infants: it’s time to stop!." The Journal of pediatrics 159.5 (2011): 707-708.

[44]- De Rose, Domenico Umberto, et al. "Stop in Time: how to reduce unnecessary antibiotics in newborns with late-onset Sepsis in neonatal intensive care." Tropical Medicine and Infectious Disease 9.3 (2024): 63.

[45]- Tomar, Priya, et al. "Simultaneous two-site blood culture for diagnosis of neonatal sepsis." Indian pediatrics 54 (2017): 199-203.

[46]- Coggins, Sarah A., Mary Catherine Harris, and Lakshmi Srinivasan. "Dual-site blood culture yield and time to positivity in neonatal late-onset sepsis." Archives of Disease in Childhood

[47]- Hajjar, Nicole, et al. "Blood culture collection practices in NICU; A national survey." Paediatrics & Child Health 28.3 (2023): 166-171.

[48]- Gottschalk, Amanda, et al. "Utility of anaerobic blood cultures in neonatal sepsis evaluation." Journal of the Pediatric Infectious Diseases Society 13.8 (2024): 406-412.

[49]- Marks, Lucinda, Koert de Waal, and John K. Ferguson. "Time to positive blood culture in early onset neonatal sepsis: a retrospective clinical study and review of the literature." Journal of paediatrics and child health 56.9 (2020): 1371-1375.

[50]- Kuzniewicz, Michael W., et al. "Time to positivity of neonatal blood cultures for early-onset sepsis." The Pediatric infectious disease journal 39.7 (2020): 634-640.

[51]- De Rose, Domenico Umberto, et al. "Time to positivity of blood cultures could inform decisions on antibiotics administration in neonatal early-onset sepsis." Antibiotics 10.2 (2021): 123.

[52]- Mukhopadhyay, Sagori, et al. "Time to positivity of blood cultures in neonatal late-onset bacteraemia." Archives of Disease in Childhood-Fetal and Neonatal Edition 107.6 (2022): 583-588.

[53]- Arias-Felipe, Ana, et al. "Determining time to positivity of blood cultures in a neonatal unit." Journal of the Pediatric Infectious Diseases Society 11.11 (2022): 510-513.

[54]- Oeser, C., et al. "Neonatal invasive fungal infection in England 2004–2010." Clinical Microbiology and Infection 20.9 (2014): 936-941.

[55]- Peri, Anna Maria, et al. "Performance of BioFire Blood Culture Identification 2 Panel (BCID2) for the detection of bloodstream pathogens and their associated resistance markers: a systematic review and meta-analysis of diagnostic test accuracy studies." BMC Infectious Diseases 22.1 (2022): 794.

[56]- Graff, Kelly E., et al. "Clinical impact of the expanded BioFire Blood Culture Identification 2 panel in a US children's hospital." Microbiology Spectrum 9.1 (2021): 10-1128.

[57]- Graff, Kelly E., et al. "Clinical impact of the expanded BioFire Blood Culture Identification 2 panel in a US children's hospital." Microbiology Spectrum 9.1 (2021): 10-1128.

[58]- Messacar, Kevin, et al. "Clinical impact and provider acceptability of real-time antimicrobial stewardship decision support for rapid diagnostics in children with positive blood culture results." Journal of the Pediatric Infectious Diseases Society 6.3 (2017): 267-274.

[59]- Lucignano B., Cento V., Agosta M., Ambrogi F., Albitar-Nehme S., Mancinelli L., Mattana G., Onori M., Galaverna F., Di Chiara L., et al. Effective Rapid Diagnosis of Bacterial and Fungal Bloodstream Infections by T2 Magnetic Resonance Technology in the Pediatric Population. J. Clin. Microbiol. 2022;60:e00292-22. doi: 10.1128/jcm.00292-22.

[60]- Schmatz, Melissa, et al. "Surviving sepsis in a referral neonatal intensive care unit: association between time to antibiotic administration and in-hospital outcomes." The Journal of Pediatrics 217 (2020): 59-65.

[61]- Prusakov, Pavel, et al. "A global point prevalence survey of antimicrobial use in neonatal intensive care units: The no-more-antibiotics and resistance (NO-MAS-R) study." EClinicalMedicine 32 (2021).

[62]- But, Špela, Brigita Celar, and Petja Fister. "Tackling Neonatal Sepsis—Can It Be Predicted?." International Journal of Environmental Research and Public Health 20.4 (2023): 3644.

[63]- Boscarino, Giovanni, et al. "Biomarkers of neonatal sepsis: where we are and where we are going." Antibiotics 12.8 (2023): 1233.

[64]- Dong, Ying, and Christian P. Speer. "Late-onset neonatal sepsis: recent developments." Archives of Disease in Childhood-Fetal and Neonatal Edition 100.3 (2015): F257-F263.

[65]- Cantey, Joseph B., and John H. Lee. "Biomarkers for the diagnosis of neonatal sepsis." Clinics in perinatology 48.2 (2021): 215-227.

[66]- Maddaloni, Chiara, et al. "The emerging role of presepsin (P-SEP) in the diagnosis of sepsis in the critically ill infant: a literature review." International journal of molecular sciences 22.22 (2021): 12154.

[67]- Maddaloni, Chiara, et al. "Perinatal asphyxia does not influence presepsin levels in neonates: a prospective study." Acta Paediatrica 113.3 (2024): 453-460.

[68]- Stocker, Martin, and Eric Giannoni. "Game changer or gimmick: inflammatory markers to guide antibiotic treatment decisions in neonatal early-onset sepsis." Clinical Microbiology and Infection 30.1 (2024): 22-27.

[69]- van Leeuwen, Lisanne M., et al. "Diagnostic value of maternal, cord blood and neonatal biomarkers for early onset sepsis: a systematic review and meta-analysis." Clinical Microbiology and Infection (2024).

[70]- Brown, Jennifer Valeska Elli, et al. "Assessment of C-reactive protein diagnostic test accuracy for late-onset infection in newborn infants: a systematic review and meta-analysis." JAMA pediatrics 174.3 (2020): 260-268.

[71]- Stocker, Martin, et al. "Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns)." The Lancet 390.10097 (2017): 871-881.

[72]- Meem, Mahbuba, et al. "Biomarkers for diagnosis of neonatal infections: A systematic analysis of their potential as a point-of-care diagnostics." Journal of global health 1.2 (2011): 201.

[73]- Aloisio, Elena, Alberto Dolci, and Mauro Panteghini. "Procalcitonin: Between evidence and critical issues." Clinica chimica acta 496 (2019): 7-12.

[74]- Poggi, Chiara, et al. "Presepsin for the detection of late-onset sepsis in preterm newborns." Pediatrics 135.1 (2015): 68-75.

[75]- Rayan, Jehan. "Presepsin as an early reliable diagnostic and prognostic marker of neonatal sepsis." International Journal 4.6 (2016): 1538-1549.

[76]- Miyosawa, Yukihide, et al. "Presepsin as a predictor of positive blood culture in suspected neonatal sepsis." Pediatrics International 60.2 (2018): 157-161.

[77]- Von Groote, Thilo, and Melanie Meersch-Dini. "Biomarkers for the Prediction and Judgement of Sepsis and Sepsis Complications: A Step towards precision medicine?." Journal of Clinical Medicine 11.19 (2022): 5782.

[78]- Pierrakos, Charalampos, et al. "Biomarkers of sepsis: time for a reappraisal." Critical Care 24 (2020): 1-15.

[79]- Sanz Codina, Maria, and Markus Zeitlinger. "Biomarkers predicting tissue pharmacokinetics of antimicrobials in sepsis: a review." Clinical Pharmacokinetics 61.5 (2022): 593-617.

[80]- Póvoa, Pedro, et al. "How to use biomarkers of infection or sepsis at the bedside: guide to clinicians." Intensive care medicine 49.2 (2023): 142-153.

[81]- Hung, Shang-Kai, et al. "Current evidence and limitation of biomarkers for detecting sepsis and systemic infection." Biomedicines 8.11 (2020): 494.

[82]- Kim, Mi-Hee, and Jung-Hyun Choi. "An update on sepsis biomarkers." Infection & chemotherapy 52.1 (2020): 1.

[83]- Barichello, Tatiana, et al. "Biomarkers for sepsis: more than just fever and leukocytosis—a narrative review." Critical care 26.1 (2022): 14.

[84]- Kang, Rui, et al. "HMGB1 in health and disease." Molecular aspects of medicine 40 (2014): 1-116.

[85]- Lu, Bin, et al. "The utility of presepsin in diagnosis and risk stratification for the emergency patients with sepsis." The American Journal of Emergency Medicine 36.8 (2018): 1341-1345.

[86]- Xiao, Hongli, et al. "Potential value of presepsin guidance in shortening antibiotic therapy in septic patients: a multicenter, prospective cohort trial." Shock 57.1 (2022): 63-71.

[87]- Patnaik, Rupali, Afzal Azim, and Vikas Agarwal. "Neutrophil CD64 a diagnostic and prognostic marker of sepsis in adult critically ill patients: A brief review." Indian journal of critical care medicine: peer-reviewed, official publication of Indian Society of Critical Care Medicine 24.12 (20Sanger, Heinz L., et al. "Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures." Proceedings of the National Academy of Sciences 73.11 (1976): 3852-3856.20): 1242.

[88]- Cao, Changlin, Jingxian Gu, and Jingyao Zhang. "Soluble triggering receptor expressed on myeloid cell-1 (sTREM-1): a potential biomarker for the diagnosis of infectious diseases." Frontiers of medicine 11 (2017): 169-177.

[89]- Sanger, Heinz L., et al. "Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures." Proceedings of the National Academy of Sciences 73.11 (1976): 3852-3856.

[90]- Feng, Kaixuan, et al. "Knockdown of lncRNA-ASLNC12002 alleviates epithelial–mesenchymal transition of type II alveolar epithelial cells in sepsis-induced acute respiratory distress syndrome." Human cell 36.2 (2023): 568-582.

[91]-

[88]- Cao, Changlin, Jingxian Gu, and Jingyao Zhang. "Soluble triggering receptor expressed on myeloid cell-1 (sTREM-1): a potential biomarker for the diagnosis of infectious diseases." Frontiers of medicine 11 (2017): 169-177.

[84]- Garrido, Felipe, et al. "Variations in antibiotic use and sepsis management in neonatal intensive care units: a European Survey." Antibiotics 10.9 (2021): 1046.

[85]- Adams, Mark, and Dirk Bassler. "Practice variations and rates of late onset sepsis and necrotizing enterocolitis in very preterm born infants, a review." Translational pediatrics 8.3 (2019): 212.

[86]- Litz, Jana E., et al. "Management of early-and late-onset sepsis: results from a survey in 80 German NICUs." Infection 47 (2019): 557-564.

[87]- Poggi, Chiara, and Carlo Dani. "New antimicrobials for the treatment of neonatal sepsis caused by multi-drug-resistant bacteria: a systematic review." Antibiotics 12.6 (2023): 956.

[88]- Gominet, Marie, et al. "Central venous catheters and biofilms: where do we stand in 2017?." Apmis 125.4 (2017): 365-375.

[89]- Mermel, Leonard A., et al. "Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America." Clinical infectious diseases 49.1 (2009): 1-45.

[90]- Piersigilli, Fiammetta, et al. "Use of meropenem and other antimicrobial lock therapy in the treatment of catheter-related blood stream infections in neonates: a retrospective study." Children 9.5 (2022): 614.

[91]- Savarese, Immacolata, et al. "Use of 2% taurolidine lock solution for treatment and prevention of catheter-related bloodstream infections in neonates: a feasibility study." Journal of Hospital Infection 143 (2024): 76-81.

[92]- Esposito, Susanna, and Nicola Principi. "Adjunctive therapy to treat neonatal sepsis." Expert review of clinical pharmacology 13.1 (2020): 65-73.

[93]- Alejandria, Marissa M., et al. "Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock." Cochrane Database of Systematic Reviews 9 (2013).

[94]- Savarese, Immacolata, et al. "Use of 2% taurolidine lock solution for treatment and prevention of catheter-related bloodstream infections in neonates: a feasibility study." Journal of Hospital Infection 143 (2024): 76-81.

[95]- Nassir, Kawthar F., et al. "Pentaglobin (immunoglobulin M-enriched immunoglobulin) as adjuvant therapy for premature and very low-birth-weight neonates with sepsis." Indian journal of pharmacology 53.5 (2021): 364-370.

[96]- O'Reilly, Daniel, et al. "Platelets in pediatric and neonatal sepsis: novel mediators of the inflammatory cascade." Pediatric Research 91.2 (2022): 359-367.

[97]- Curley, Anna, et al. "Randomized trial of platelet-transfusion thresholds in neonates." New England Journal of Medicine 380.3 (2019): 242-251.

[98]- Mathias, Sitarah, et al. "The effect of exchange transfusion on mortality in neonatal sepsis: A meta-analysis." European Journal of Pediatrics (2022): 1-13.

[99]- Fairchild, Karen D., and T. Michael O'Shea. "Heart rate characteristics: physiomarkers for detection of late-onset neonatal sepsis." Clinics in perinatology 37.3 (2010): 581-598.

[100]- Rio, Laura, et al. "Monitoring of heart rate characteristics to detect neonatal sepsis." Pediatric Research 92.4 (2022): 1070-1074.

[101]- Hicks, Jamie H., and Karen D. Fairchild. "Heart rate characteristics in the NICU: what nurses need to know." Advances in Neonatal Care 13.6 (2013): 396-401.

[102]- Moorman, Joseph Randall, et al. "Mortality reduction by heart rate characteristic monitoring in very low birth weight neonates: a randomized trial." The Journal of pediatrics 159.6 (2011): 900-906.

[103]- Fairchild, Karen D. "Predictive monitoring for early detection of sepsis in neonatal ICU patients." Current opinion in pediatrics 25.2 (2013): 172-179.

[104]- Zeigler, Angela C., et al. "Sepsis and mortality prediction in very low birth weight infants: analysis of HeRO and nSOFA." American journal of perinatology 40.04 (2023): 407-414.

[105]- Pugnaloni, Flaminia, et al. "Assessment of hemodynamic dysfunction in septic newborns by functional echocardiography: a systematic review." Pediatric Research 95.6 (2024): 1422-1431.

[106]- Sullivan, Brynne A., Sherry L. Kausch, and Karen D. Fairchild. "Artificial and human intelligence for early identification of neonatal sepsis." Pediatric research 93.2 (2023): 350-356.

[107]- Stocker, Martin, et al. "Machine learning used to compare the diagnostic accuracy of risk factors, clinical signs and biomarkers and to develop a new prediction model for neonatal early-onset sepsis." The Pediatric Infectious Disease Journal 41.3 (2022): 248-254.